BOC Sciences Introduces Varieties of Small Molecule Inhibitors for Drug Discovery Research

BOC Sciences, a chemical company that has been actively involved in advancing drug development for the wellbeing of mankind with concerted efforts from the industry, announces to introduce more varieties of small molecule inhibitors, such as Antibacterial Inhibitor, CD28 Inhibitor, HHLA2 Inhibitor, Antifungal Inhibitor, Antiparasitic Inhibitor, APC Inhibitor, Bcr-Abl Inhibitor, BCRP Inhibitor

On March 26, 2019, BOC Sciences, a chemical company that has been actively involved in advancing drug development for the wellbeing of mankind with concerted efforts from the industry, announces to introduce more varieties of small molecule inhibitors, such as Antibacterial Inhibitor, CD28 Inhibitor, HHLA2 Inhibitor, Antifungal Inhibitor, Antiparasitic Inhibitor, APC Inhibitor, Bcr-Abl Inhibitor, BCRP Inhibitor. After this move, a total of more than 300, 000 chemicals are within BOC Sciences’ database and can be easily obtained by researchers and scientists.

Small molecule inhibitors are a well-established class of potential useful drugs. Compared with large molecule drug candidates like peptides, inhibitors seem to be more favored and are widely applied in all kinds of fields of medical and pharmaceutical research, targeting diseases like cancer, neurological disease, infectious disease, metabolic disease and so on. Moreover, in addition to their therapeutic potentials as treatment of a number of diseases, small molecule inhibitors can also be used in conjunction with other treatments, such as RNA interference (RNAi).

“The past decade has seen a drastic increase in the demand for the new and novel inhibitor chemicals since there are so many diseases that haven’t been conquered,” says Mr. Barron Jones, the Marketing Chief of BOC Sciences. “It is out of consideration for this that we decide to broaden our collection of novel inhibitor categories for the convenience of our clients who are seeking for those chemicals for their latest research.”

For more information about BOC Sciences’ newly updated therapeutic inhibitors, please visit: https://www.bocsci.com/inhibitor-list-84.html

Antibacterial Inhibitor

As the antibiotic classes currently used in clinical practice target only a limited number of cellular functions (cell wall biosynthesis, nucleic acid metabolism, protein biosynthesis or DNA replication), it is urgent to identify novel compounds that inhibit biosynthetic pathways presently not addressed by current antibacterials. Antibacterial inhibitors like LAH4, Levofloxacin, Rufloxacin, Tigemonam, Cadazolid, Sulfaclozine are available at BOC Sciences.

BCRP Inhibitor

BCRP has been reported in breast cancer, lung cancer, leukemia and other malignant tumors. It was also found that specific inhibitors have inhibitory effects on BCRP, such as FTA, a mycotoxin fumitremorgin C. Besides, some topotecan derivatives are also specific inhibitors of ABCG2.

CD28 Inhibitor

As one of the proteins expressed on T cells, CD28 plays an important role in autoimmune disease, transplant rejection, tumor immunity and aging. The regulation of CD28 involves the initiation, expansion, maintenance and down-regulation of the immune response.

About BOC Sciences

To meet needs in fields like agriculture, biotechnology, pharmaceutical, BOC Sciences not only offers a full-ranged collection of various chemicals at both research and industrial scale, but also offers multiple professional services like chiral resolution, custom synthesis, drug discovery, CMO service, facilitating client’s’ efforts in drug discovery and research.